Newsletter | April 6, 2026

04.06.26 -- STREAM Progress: Innovations Powering The Path To The Patient

SPONSOR

Webinar: From DNA to IND in as little as 6 months: Fast to clinic, designed to scale, backed by experience

Accelerating antibody development requires smarter strategy. In this webinar, Lonza explores how an integrated CMC approach can move programs from DNA to IND in as little as six months. Learn how platform technologies, parallel workflows, and CDMO collaboration reduce risk, avoid bottlenecks, and support faster biologics development. Click here to learn more.

Navigating Primary Packaging Challenges For Emerging Innovators

Webinar | West Pharmaceutical Services, Inc.

If you are in the process of developing a complex or sensitive injectable drug, learn about containment solutions to mitigate your risks and help you get your drug to the patient faster.

Game-Changing CLD Platforms: Strategies, Technologies, Workflows

Webinar | Abzena

Selecting the right cell line platform is complex. Learn how flexible strategies, integrated technologies, and expert workflows enable high productivity, rapid timelines, and a de-risked path to clinical success.

New Approaches To Tailored Release Profiles

Video | Adare Pharma Solutions

Tailored drug release is evolving from formulation tactic to precision therapy strategy, optimizing timing, site, and rate of delivery for improved patient outcomes.

Combining Cell Line Development Innovation To Streamline Path To FIH

Webinar | KBI Biopharma

Explore how our technology platform accelerates the development of complex biologics from early stages to first-in-human (FIH) trials, focusing on both speed and quality.

The BioSecure Act And Unfiltered Supply Chain Realities

Video | Outsourced Pharma

This segment of the Outsourced Pharma Live event, “The Unfiltered Truth About CDMO Selection”, addresses the critical necessity of gaining supplier-level visibility for raw materials and packaging amidst geopolitical risks, while exploring the unfiltered reality that technology transfers to established US-based suppliers take significant time and capital to execute properly.

Lonza Capabilities Update March 2026: Cell & Gene Therapy

Video | Lonza

A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.

Connect With Outsourced Pharma: